Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別) 在庫  
In DMSO JPY 17100 あり
JPY 13600 あり
JPY 26900 あり
JPY 46800 あり
JPY 129800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(270)

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M1q3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\uNWlEPTB;MD6wOlEh|ryP MVTTRW5ITVJ?
ALL-PO M{DWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi0RlhKSzVyPUCuNFY{PTVizszN NUPVcYNtW0GQR1XS
697 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrmbVdKSzVyPUCuNFk6PzZizszN M4\tbnNCVkeHUh?=
NCI-H748 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17XXGlEPTB;MD6xNFM{PCEQvF2= MUTTRW5ITVJ?
NKM-1 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETtZ49KSzVyPUCuNVA6OTJizszN NYf3UoVuW0GQR1XS
ES1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTsbJZSUUN3ME2wMlEyOjV3IN88US=> NV\pc4RDW0GQR1XS
NCI-H1963 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XiOmlEPTB;MD6xNVU4QSEQvF2= M4rPUnNCVkeHUh?=
NCI-H1417 M1ztd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PRRWlEPTB;MD6xNlk4PCEQvF2= MXfTRW5ITVJ?
NEC8 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMUO1Nlch|ryP MoDUV2FPT0WU
CRO-AP2 NVPZUIZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL2doJKSzVyPUCuNVY5QDlizszN NEDIXpBUSU6JRWK=
A3-KAW NGroR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDwTWM2OD1yLkG3OlI4KM7:TR?= NXHicnVUW0GQR1XS
SF539 M{TDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3aXFdKSzVyPUCuNVk2QTNizszN MYTTRW5ITVJ?
NOS-1 M2LneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHwbGttUUN3ME2wMlE6PjF7IN88US=> MnnYV2FPT0WU
NTERA-S-cl-D1 NYKyXIJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrWTWM2OD1yLkKwNVE{KM7:TR?= M{PPT3NCVkeHUh?=
COR-L88 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXaO|hKSzVyPUCuNlI6PTlizszN NHeyR|RUSU6JRWK=
EM-2 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3kNWl3UUN3ME2wMlI1ODd7IN88US=> MoLlV2FPT0WU
KARPAS-45 M{XuVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMke4N|Mh|ryP MlPvV2FPT0WU
DSH1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHGXJc1UUN3ME2wMlI5PzB6IN88US=> MmnLV2FPT0WU
HT-144 M4e3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX2TWM2OD1yLkOwNlU3KM7:TR?= NWK3emdMW0GQR1XS
ATN-1 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLkTWM2OD1yLkOwOVc3KM7:TR?= NVvjVnVYW0GQR1XS
HEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;3Z4t5UUN3ME2wMlMyOzR6IN88US=> M1ziZ3NCVkeHUh?=
NB12 NInwdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnxRmJIUUN3ME2wMlMyPzV4IN88US=> NYPWOWx3W0GQR1XS
LU-139 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwM{O1NUDPxE1? NGrrUVJUSU6JRWK=
J-RT3-T3-5 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\o[o0xUUN3ME2wMlM{PzF4IN88US=> Mmr5V2FPT0WU
MOLT-13 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO0T4VDUUN3ME2wMlM{QDFizszN MYPTRW5ITVJ?
SR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfoO4VTUUN3ME2wMlM1OjZzIN88US=> NVvQbIE3W0GQR1XS
CMK NGTZ[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\2VVNKSzVyPUCuN|U4OjdizszN MWrTRW5ITVJ?
ES8 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fDOWlEPTB;MD6zOlAzOiEQvF2= M3PxPXNCVkeHUh?=
LB647-SCLC Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwM{[3N{DPxE1? M{H6OnNCVkeHUh?=
TE-8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[5S3JKSzVyPUCuN|Y6OzVizszN NHz3T25USU6JRWK=
BV-173 NX;C[ZpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwM{exNlEh|ryP MXLTRW5ITVJ?
DEL MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v2emlEPTB;MD6zO|Q5PyEQvF2= NGf5eJlUSU6JRWK=
ARH-77 NVv6Opg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrPTWM2OD1yLkO4NVk{KM7:TR?= NXzlNYlWW0GQR1XS
NCCIT NYLoUmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwM{i2OFkh|ryP NF;MfWhUSU6JRWK=
RPMI-8402 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwM{i3NFEh|ryP NGG2fHZUSU6JRWK=
MONO-MAC-6 NGTMZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2zTWM2OD1yLkO4O|c3KM7:TR?= NHXvU4lUSU6JRWK=
SK-MM-2 NXfIZ21ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfCTWM2OD1yLkO5PFY5KM7:TR?= M{nSbHNCVkeHUh?=
CHP-126 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDYRoFPUUN3ME2wMlQxOjNzIN88US=> MmDGV2FPT0WU
A101D M{f2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j6ZWlEPTB;MD60NFMh|ryP M{XCbHNCVkeHUh?=
SCH NILT[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTZTWM2OD1yLkSwN|QzKM7:TR?= NEfMfIVUSU6JRWK=
NMC-G1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vFUWlEPTB;MD60NFM3PyEQvF2= NUHWS|lyW0GQR1XS
NCI-H209 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPQTWM2OD1yLkSwOlE{KM7:TR?= NIDmc3JUSU6JRWK=
MOLT-16 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H0e2lEPTB;MD60NVAyPyEQvF2= MoDkV2FPT0WU
RPMI-6666 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;lTWM2OD1yLkSxNVIh|ryP NXvMXIZMW0GQR1XS
OPM-2 NVT1W2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHVfXZWUUN3ME2wMlQyPTF|IN88US=> NXv4OYVkW0GQR1XS
MRK-nu-1 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPSWlQ4UUN3ME2wMlQ{OTV|IN88US=> MkHLV2FPT0WU
BC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vYPGlEPTB;MD60N|QxOyEQvF2= MYrTRW5ITVJ?
MHH-NB-11 MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q3Z2lEPTB;MD60N|Q2OyEQvF2= NY[2WpR1W0GQR1XS
Ramos-2G6-4C10 M4jQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNEO4PVch|ryP MonEV2FPT0WU
LS-513 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\y[WlEPTB;MD60OFUxOSEQvF2= MkDRV2FPT0WU
K5 NX\JfnFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\P[4JKSzVyPUCuOFcxOjVizszN M{nDeXNCVkeHUh?=
HOP-62 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP2SnlKSzVyPUCuOFg{PThizszN MknxV2FPT0WU
NCI-H187 NEjoT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSyTHhKSzVyPUCuOFkzOjdizszN NH\MO2dUSU6JRWK=
BE-13 NEnDd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jEcWlEPTB;MD60PVY3OSEQvF2= MlHlV2FPT0WU
HC-1 NGD1OnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO5N5lKSzVyPUCuOVA1PzNizszN NUnwPFVOW0GQR1XS
ACN MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwNUGwNlgh|ryP MVfTRW5ITVJ?
HCC1599 NUn0dWRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHEO3FtUUN3ME2wMlUyPTdizszN NXz0RXl2W0GQR1XS
MV-4-11 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;yeVJIUUN3ME2wMlU{ODRzIN88US=> NEDsVXFUSU6JRWK=
LC-2-ad M4X1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf4PHlEUUN3ME2wMlU{PjZ|IN88US=> NYTLWnJsW0GQR1XS
HL-60 NVLnSppJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNUSyOlEh|ryP MUHTRW5ITVJ?
NB17 NXTGOZE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP1OHdKSzVyPUCuOVQ{QCEQvF2= MnjOV2FPT0WU
TE-1 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwNUWzNFYh|ryP NVHkfWdtW0GQR1XS
NCI-H524 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLkTWM2OD1yLkW1OFAyKM7:TR?= MoDwV2FPT0WU
MZ7-mel MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwNU[xNFUh|ryP M17ubHNCVkeHUh?=
L-363 M1zzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLCTWM2OD1yLkW2OlU4KM7:TR?= NYfufXltW0GQR1XS
BL-41 NEnod3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3tVWZKSzVyPUCuOVY5QDlizszN MYjTRW5ITVJ?
LU-134-A MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwNUewO|Mh|ryP M2\zOHNCVkeHUh?=
SIG-M5 NHzwV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwNUe4OFgh|ryP NFLrOY1USU6JRWK=
ONS-76 M2fhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;qVXJzUUN3ME2wMlU5OjR{IN88US=> M{H2fHNCVkeHUh?=
KARPAS-299 M3;x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwNUi1NFQh|ryP MWjTRW5ITVJ?
DU-4475 M2LmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTpRYpNUUN3ME2wMlU5PzB|IN88US=> NVj5e3RyW0GQR1XS
NB69 M1LUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{K1UGlEPTB;MD61PVgzPSEQvF2= MUTTRW5ITVJ?
MHH-PREB-1 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i2e2lEPTB;MD62NFcyQSEQvF2= M4Hh[3NCVkeHUh?=
LU-165 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj5e4dKSzVyPUCuOlE5OTJizszN Mn7VV2FPT0WU
LOUCY M2Hqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;PTWM2OD1yLk[zN|Y1KM7:TR?= NGDUNlZUSU6JRWK=
NCI-H526 NYKwS4xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7sZYtKSzVyPUCuOlM2PDFizszN NHz2N49USU6JRWK=
KE-37 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwNkSyO|Yh|ryP NXH5OFZFW0GQR1XS
NALM-6 NHvCPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\qTWM2OD1yLk[0PFYh|ryP NFnwPGNUSU6JRWK=
CW-2 Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTvTWM2OD1yLk[1O|k1KM7:TR?= MmrnV2FPT0WU
SU-DHL-1 NGTidJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLVe2JwUUN3ME2wMlY2QTR5IN88US=> MVfTRW5ITVJ?
NB13 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu4UoI1UUN3ME2wMlY3QDF5IN88US=> M3j4W3NCVkeHUh?=
QIMR-WIL NID5T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDDd4xKSzVyPUCuOlg{PDNizszN M2D6UHNCVkeHUh?=
ECC12 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLPTWM2OD1yLkewNFg3KM7:TR?= M374NXNCVkeHUh?=
KALS-1 NXLHcplXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r6OWlEPTB;MD63NFQ6OiEQvF2= NGLDVFNUSU6JRWK=
COR-L279 NHzOd2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LXc2lEPTB;MD63NFk6PiEQvF2= MWrTRW5ITVJ?
NB14 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q0[GlEPTB;MD63NlYyPyEQvF2= MonnV2FPT0WU
CCRF-CEM NWfO[5RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwN{S2OlEh|ryP Mn61V2FPT0WU
SW954 Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLqT4lKSzVyPUCuO|U6QTlizszN MXzTRW5ITVJ?
IST-SL1 NILLWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLYd4ZKSzVyPUCuO|c{PDhizszN MUPTRW5ITVJ?
LAMA-84 M{nVR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIi2TYhKSzVyPUCuO|c2PjdizszN MVfTRW5ITVJ?
Daudi MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XjSmlEPTB;MD63O|Y5OSEQvF2= NYLIfIFQW0GQR1XS
BC-3 NYPSSVFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\kSGZKSzVyPUCuO|g{ODhizszN MorBV2FPT0WU
HCC2998 NHvWW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETBVmdKSzVyPUCuO|g{PiEQvF2= NHrtUXFUSU6JRWK=
NCI-H69 NVLsXmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4W3[GlEPTB;MD64NFE1PyEQvF2= MWTTRW5ITVJ?
CPC-N M1zwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSyOGhKSzVyPUCuPFA2OjRizszN MUXTRW5ITVJ?
NOMO-1 M2i2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPuc|NsUUN3ME2wMlgyODh2IN88US=> MWjTRW5ITVJ?
CESS MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPFTWM2OD1yLkixNVk4KM7:TR?= NGGwRWxUSU6JRWK=
LC4-1 Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r1T2lEPTB;MD64OFAxPyEQvF2= NXPESW05W0GQR1XS
BL-70 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqzcIxKSzVyPUCuPFU4ODJizszN M33ifHNCVkeHUh?=
ES4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HFT2lEPTB;MD64OVg3QCEQvF2= M{LUfHNCVkeHUh?=
HCE-T M1jsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrzTWM2OD1yLki3NVcyKM7:TR?= MUfTRW5ITVJ?
JAR Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljFTWM2OD1yLki3PFI4KM7:TR?= MY\TRW5ITVJ?
ST486 NYr6b25bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjuTmxPUUN3ME2wMlg4QTF5IN88US=> M4DQUnNCVkeHUh?=
KS-1 M{\xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnMd|RkUUN3ME2wMlg5ODl4IN88US=> NVmz[2J2W0GQR1XS
GDM-1 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrjTmVXUUN3ME2wMlg5Pjh5IN88US=> NGLsOYJUSU6JRWK=
EHEB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\FUmlEPTB;MD65NlU5PSEQvF2= MXLTRW5ITVJ?
LB2518-MEL Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq4cY4xUUN3ME2wMlk{Ojh2IN88US=> M3zVPXNCVkeHUh?=
GOTO MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwOUWwO|Yh|ryP MljYV2FPT0WU
LXF-289 MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LadmlEPTB;MD65OVkxOSEQvF2= NXvscolVW0GQR1XS
ES6 NWTVd|dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3yeYNSUUN3ME2wMlk3PDN5IN88US=> MVzTRW5ITVJ?
OS-RC-2 NWTJXnlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3jTWM2OD1yLkm2PFMh|ryP MVXTRW5ITVJ?
DMS-153 NFnRbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmn1TWM2OD1yLkm3OFY6KM7:TR?= MUfTRW5ITVJ?
SK-PN-DW Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\kVYtKSzVyPUCuPVc5OzFizszN NGT4WYJUSU6JRWK=
HH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HkUWlEPTB;MD65PFk2QSEQvF2= NF7hZmxUSU6JRWK=
SH-4 M17TR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTVTFNlUUN3ME2xMlAzPDFizszN MoPyV2FPT0WU
MOLT-4 NFm5VFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjCdY4xUUN3ME2xMlA{PDV2IN88US=> M3;DdXNCVkeHUh?=
TGW NUm2XnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHaRVdKSzVyPUGuNFc3PzVizszN NEDsbnpUSU6JRWK=
L-540 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTWTWM2OD1zLkGwOlA1KM7:TR?= Mo\qV2FPT0WU
PF-382 NIKwS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7Ud3ZKSzVyPUGuNVE2OTNizszN MY\TRW5ITVJ?
LC-1F MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfaTWM2OD1zLkGyNFA4KM7:TR?= NVrhcIZQW0GQR1XS
OVCAR-4 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnOcYJKSzVyPUGuNVMyPjVizszN MYrTRW5ITVJ?
A4-Fuk NXzsWXo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzUZoc4UUN3ME2xMlE2OzZ2IN88US=> MXjTRW5ITVJ?
HCC2218 M3PpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHCSo5qUUN3ME2xMlE3PjRzIN88US=> Ml3lV2FPT0WU
HAL-01 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwMU[5OFMh|ryP NGroOodUSU6JRWK=
IST-MEL1 M{[3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[xeHJKSzVyPUGuNVc3PTlizszN MVHTRW5ITVJ?
NCI-H719 MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwMUe4PVgh|ryP NVTVZlVjW0GQR1XS
EVSA-T NWSzXGdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq4dVZlUUN3ME2xMlE5OTF2IN88US=> M1XDTnNCVkeHUh?=
SK-NEP-1 Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH20WpFKSzVyPUGuNlAzPjZizszN MWXTRW5ITVJ?
OCUB-M MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwMkG0PFkh|ryP NUPtb|NKW0GQR1XS
MEG-01 M1TqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjtUGQ4UUN3ME2xMlIzOTF6IN88US=> MVvTRW5ITVJ?
no-10 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fTemlEPTB;MT6yN|EyOiEQvF2= M1\YdHNCVkeHUh?=
MHH-CALL-2 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rCWWlEPTB;MT6yOFczOSEQvF2= NYLDNGVlW0GQR1XS
SK-N-DZ MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXpN29KSzVyPUGuNlQ4PzZizszN M{LCSXNCVkeHUh?=
SCLC-21H NWHZTFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXjUGZKSzVyPUGuNlY1PzhizszN MXfTRW5ITVJ?
CTV-1 MnPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu5[XJYUUN3ME2xMlI4PDJ3IN88US=> MW\TRW5ITVJ?
NB1 NVfLW2o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr5WnVKSzVyPUGuNlc4OzJizszN MVzTRW5ITVJ?
NCI-H64 NHX0d5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDRdFZlUUN3ME2xMlI5PDZ{IN88US=> NYXSSmJkW0GQR1XS
MDA-MB-134-VI NV3IfmlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGruOY1KSzVyPUGuNlg2PzdizszN MUXTRW5ITVJ?
LB2241-RCC Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofHTWM2OD1zLkK4OlY{KM7:TR?= Mo\aV2FPT0WU
8-MG-BA NUS4[Wd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fzVGlEPTB;MT6yPFg3PiEQvF2= NEPoZ|NUSU6JRWK=
LP-1 M2LS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm3SHJqUUN3ME2xMlI6QTR5IN88US=> MkfkV2FPT0WU
LS-411N MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LHOWlEPTB;MT6zNFk6QCEQvF2= MkHkV2FPT0WU
CAL-148 NWLJe|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;vTGlEPTB;MT6zNlU1OiEQvF2= NXzLOWhmW0GQR1XS
NCI-H2171 M3;K[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e3XWlEPTB;MT6zOFUxOiEQvF2= M3zVVHNCVkeHUh?=
JiyoyeP-2003 NUHGbGlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTYZVhKSzVyPUGuN|U{QSEQvF2= NV\x[WtiW0GQR1XS
NCI-H2107 M2jLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwM{W4PFMh|ryP MnXtV2FPT0WU
BB30-HNC NFqzV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwM{i5O|gh|ryP NFXJSWZUSU6JRWK=
K-562 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLIWZB[UUN3ME2xMlM6OjF7IN88US=> MkjVV2FPT0WU
PSN1 MlPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7EbHhKSzVyPUGuOFIzQDdizszN NV\WWot7W0GQR1XS
HCC2157 NVv4cINHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH4TWM2OD1zLkSyOlkyKM7:TR?= NF\EU3RUSU6JRWK=
SBC-1 NFXhNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHWdWJ6UUN3ME2xMlQzPzRzIN88US=> M2HFVXNCVkeHUh?=
MC116 NHPQPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzqcZBKSzVyPUGuOFM3OTVizszN NGfQ[Y1USU6JRWK=
KARPAS-422 M3\QW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLVe3dKSzVyPUGuOFU{PThizszN MlOzV2FPT0WU
LB996-RCC Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrHNppKSzVyPUGuOFcyODNizszN NYf4c3pYW0GQR1XS
MSTO-211H NEC1[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnywTWM2OD1zLkS3PVg4KM7:TR?= NWX5d5JbW0GQR1XS
BT-474 MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvRTWM2OD1zLkWxO|Y1KM7:TR?= NYHRNIlCW0GQR1XS
A388 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3NTWM2OD1zLkWxPVQ2KM7:TR?= M{XUWHNCVkeHUh?=
SJSA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfHVXdKSzVyPUGuOVIzPiEQvF2= NUHGZ5Q5W0GQR1XS
COLO-829 NX3mepNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwNUO1OlQh|ryP M2rqfnNCVkeHUh?=
KM-H2 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwNU[2O{DPxE1? NHzuOIFUSU6JRWK=
GR-ST NXHudo5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H3emlEPTB;MT61OlgzKM7:TR?= M1LkPHNCVkeHUh?=
RPMI-8866 M2O3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqzTWM2OD1zLk[wNVQ1KM7:TR?= MXPTRW5ITVJ?
KG-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwNkG5NFEh|ryP Mn:wV2FPT0WU
NCI-H82 NF7IXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXPTWM2OD1zLk[zOFA3KM7:TR?= MX;TRW5ITVJ?
LB1047-RCC MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[zS2JKSzVyPUGuOlM1PTlizszN Mn[xV2FPT0WU
KM12 M1jRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rNSWlEPTB;MT62OFch|ryP NELEd3pUSU6JRWK=
NB5 M2fweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W2eGlEPTB;MT62OVY4PyEQvF2= MWjTRW5ITVJ?
HDLM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonpTWM2OD1zLk[4NlgyKM7:TR?= MlvGV2FPT0WU
KU812 M4DVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofuTWM2OD1zLk[5OlA2KM7:TR?= MVXTRW5ITVJ?
DB NV7z[WVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\yTWM2OD1zLkewN|U{KM7:TR?= M3K5cnNCVkeHUh?=
HD-MY-Z NU[xc2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknTTWM2OD1zLke1NlM1KM7:TR?= Mn31V2FPT0WU
KURAMOCHI NVLvOXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFwN{eyNFch|ryP MkTNV2FPT0WU
ETK-1 NHTubI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7HR4RKSzVyPUGuO|g5PzlizszN NXe0c4N3W0GQR1XS
SK-UT-1 M13tfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL3U294UUN3ME2xMlc6Ozh6IN88US=> MnviV2FPT0WU
HUTU-80 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwN{m1NFgh|ryP MYjTRW5ITVJ?
ES7 NHKxcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPWfVFKSzVyPUGuPFA{ODJizszN NYfiWZZQW0GQR1XS
SW872 NWOxUnY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwOEGzPVUh|ryP M{j3[HNCVkeHUh?=
TK10 M4jT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTq[FJRUUN3ME2xMlg{OTB6IN88US=> MkPzV2FPT0WU
LB831-BLC NGn2ZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG2dmpKSzVyPUGuPFM2PjNizszN MlnoV2FPT0WU
TE-9 NYDOVYV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnMZ2xKSzVyPUGuPFQ1OjJizszN MYTTRW5ITVJ?
MLMA MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwOEiyN|Qh|ryP NX\5[|dUW0GQR1XS
D-542MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\BfIpKSzVyPUGuPFk{PzNizszN Mn:1V2FPT0WU
EW-16 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[zTWM2OD1zLkmyO|Ih|ryP NWjGV3dJW0GQR1XS
LOXIMVI NFLtV|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm3PYdNUUN3ME2xMlk{OjhizszN MWHTRW5ITVJ?
GB-1 NFfvNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX6TWM2OD1zLkmzPFY3KM7:TR?= NIjZUYdUSU6JRWK=
IST-SL2 M4HZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C4N2lEPTB;Mj6wNFI3OiEQvF2= NUnvT3FsW0GQR1XS
LAN-6 NYW2VpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvsSIxKSzVyPUKuNFE6PjZizszN NFjUR4NUSU6JRWK=
NCI-H510A NYPrUoNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJwMES1NFIh|ryP M4qwZ3NCVkeHUh?=
NCI-H1092 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTsRm5KSzVyPUKuNFUyOjRizszN M33qVHNCVkeHUh?=
HT MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W4cmlEPTB;Mj6xNFQ2PCEQvF2= Ml6yV2FPT0WU
RL95-2 NX;mTXJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHHTWM2OD1{LkGxOFgzKM7:TR?= MmnqV2FPT0WU
NCI-H1355 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36yfmlEPTB;Mj6xNVc6OiEQvF2= MWXTRW5ITVJ?
NCI-H720 NUXkfZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GxbGlEPTB;Mj6xOlg4OyEQvF2= M2TvRnNCVkeHUh?=
NCI-H1522 NHLSfnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjsPYlWUUN3ME2yMlIyPzJ|IN88US=> NXTnN2pbW0GQR1XS
LB373-MEL-D NUO2RoQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zWTGlEPTB;Mj6yOlkxOiEQvF2= M1f3NnNCVkeHUh?=
DG-75 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jVe2lEPTB;Mj6yO|E1QCEQvF2= M{fqenNCVkeHUh?=
ML-2 NUDtWWJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjBRoxKSzVyPUKuN|I5PTVizszN NF;DeJFUSU6JRWK=
SF126 NVrCdFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwM{OwPVQh|ryP M3K2TnNCVkeHUh?=
MPP-89 M1LSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfJTWM2OD1{LkOzNVQ2KM7:TR?= NX7ERo8zW0GQR1XS
NCI-H345 NH3sPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXkZoZKSzVyPUKuN|MzPzdizszN MnPSV2FPT0WU
LS-123 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULLOpVzUUN3ME2yMlM1QTN4IN88US=> MmqzV2FPT0WU
NB10 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHxZohkUUN3ME2yMlQyODl{IN88US=> M1GxRXNCVkeHUh?=
CGTH-W-1 NYXEdVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3kZpdKSzVyPUKuOFIzPjdizszN Mk\NV2FPT0WU
CP66-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTJwNEe3O{DPxE1? M1;sXHNCVkeHUh?=
L-428 M3uwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK1co1KSzVyPUKuOFg2OjFizszN MWHTRW5ITVJ?
DMS-79 NF36XGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXBfHJKSzVyPUKuOVQyODNizszN NV64R25zW0GQR1XS
NCI-H1882 Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwNke1OlIh|ryP NX3Bbpl1W0GQR1XS
KGN MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjkTWM2OD1{Lke2PFc3KM7:TR?= M{PZT3NCVkeHUh?=
EW-1 M3Lsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fiUmlEPTB;Mj63O|A5OyEQvF2= NXfJ[nNGW0GQR1XS
U-266 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XoXmlEPTB;Mj64OFgzOyEQvF2= MlnHV2FPT0WU
COLO-320-HSR NEfwXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnqcnpVUUN3ME2yMlg2PjRzIN88US=> M1;ReXNCVkeHUh?=
KMOE-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q0XGlEPTB;Mj64O|cyOSEQvF2= NXX6PYgxW0GQR1XS
BB49-HNC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT4SmdKSzVyPUKuPVI1QCEQvF2= MVXTRW5ITVJ?
GI-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKXWlEPTB;Mj65Nlk2PyEQvF2= MVHTRW5ITVJ?
NCI-H1304 NFL2cGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37PWGlEPTB;Mz6wNFUyOSEQvF2= MVLTRW5ITVJ?
NCI-H2227 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m4cGlEPTB;Mz6wNlA4QSEQvF2= MnjyV2FPT0WU
U-87-MG M4\2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTERZVKSzVyPUOuNFM2OTNizszN M{j3R3NCVkeHUh?=
NCI-H747 MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwMEWyNFYh|ryP NVXJZ2FRW0GQR1XS
CTB-1 NFf5d4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\WPXFKSzVyPUOuNFU{PzZizszN M4DaW3NCVkeHUh?=
RPMI-8226 NGj2PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XjUmlEPTB;Mz6xOFM4QCEQvF2= NH7nOphUSU6JRWK=
NCI-H2141 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\OTWM2OD1|LkG2OVY3KM7:TR?= NVHofVhnW0GQR1XS
IST-MES1 NXSyTGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4flVGlEPTB;Mz6xPFI4QSEQvF2= NUDYZ4V1W0GQR1XS
TE-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\1XmlEPTB;Mz6yNVM1OiEQvF2= MYHTRW5ITVJ?
UACC-257 NX[4c4JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfIVVJTUUN3ME2zMlQ{PjV7IN88US=> MkPvV2FPT0WU
SK-N-FI M1G4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTNwNEWyNlch|ryP Mn3SV2FPT0WU
MFH-ino M{HqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHaVJpKSzVyPUOuOFY2QDlizszN M3[0Z3NCVkeHUh?=
SF268 M4jrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HOXmlEPTB;Mz60PFE4PCEQvF2= NEDv[HpUSU6JRWK=
TE-12 M3nKemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHFTWM2OD1|LkWxOlk6KM7:TR?= MlrTV2FPT0WU
NB6 M4DJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfT[nZHUUN3ME2zMlU2PTZ|IN88US=> NIjlU5FUSU6JRWK=
DJM-1 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DPTWlEPTB;Mz61PVg6QSEQvF2= MmPuV2FPT0WU
MZ1-PC NHPOR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwNkG2NlQh|ryP MkH3V2FPT0WU
OCI-AML2 NHv3NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwNkK2O|Eh|ryP Ml73V2FPT0WU
NCI-H1155 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13SWmlEPTB;Mz63NFk1PyEQvF2= M{P6WXNCVkeHUh?=
RKO M{nqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvP[5JKSzVyPUOuO|cyQDlizszN NGXSfnZUSU6JRWK=
ECC4 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfsSFZKSzVyPUOuPVcyQTVizszN MkXVV2FPT0WU
BB65-RCC NXnhVFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLvTWM2OD1|Lkm3OVQ4KM7:TR?= M1PyNnNCVkeHUh?=
EB-3 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[ybmlEPTB;Mz65PVY{OyEQvF2= NIfhfJlUSU6JRWK=
SHP-77 NFTJVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6wVXRIUUN3ME20MlAxPTJ2IN88US=> M2P4WHNCVkeHUh?=
NCI-H2196 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTRwMEW2NlUh|ryP NVLlem1VW0GQR1XS
GI-ME-N NYXTPWl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPJbVRKSzVyPUSuNFY{QTlizszN M{[1RXNCVkeHUh?=
MN-60 NE\nXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW2VphlUUN3ME20MlExQDdizszN NYrxU3I4W0GQR1XS
NCI-H1694 NVjLe2pyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPQVlliUUN3ME20MlE{PDB3IN88US=> NHSzW5RUSU6JRWK=
LU-65 M2PEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\G[2lEPTB;ND6xOVM{OiEQvF2= MWrTRW5ITVJ?
NCI-H1436 NGjVOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTRwMUizN|Mh|ryP NYXRdmVSW0GQR1XS
KINGS-1 NHKwWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq3S2lKSzVyPUSuN|E1OzJizszN MnTBV2FPT0WU
GT3TKB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzTTWM2OD12LkOzNlY5KM7:TR?= M4fEZ3NCVkeHUh?=
Becker NFzzS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTRwM{ezNVIh|ryP M{\XdHNCVkeHUh?=
HCC1187 M36yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HKXmlEPTB;ND64PVY2PyEQvF2= MofyV2FPT0WU
D-502MG M1jVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LSc2lEPTB;NT6wNFQyPiEQvF2= M1rH[3NCVkeHUh?=
VA-ES-BJ Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHJZpBKSzVyPUWuNVM4PzhizszN M2ToRnNCVkeHUh?=
NB7 NX7w[41oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTVwMUSxNVIh|ryP NEXkPXFUSU6JRWK=
SW962 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWGwR3dLUUN3ME21MlM5QDF2IN88US=> M{XMPXNCVkeHUh?=
no-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnyTWM2OD13Lke2N|Q{KM7:TR?= NFHZTWxUSU6JRWK=
KNS-81-FD MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXBTWM2OD13LkmwOlk1KM7:TR?= MkjnV2FPT0WU
COLO-684 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfS[GlKSzVyPUWuPVk1QTRizszN NFrPSYNUSU6JRWK=
D-263MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fHXGlEPTB;Nj6wPFg6PSEQvF2= NUHyVItqW0GQR1XS
EW-24 M1mwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTZwMki1NUDPxE1? MWjTRW5ITVJ?
TE-10 NHj2O|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVWGlEPTB;Nj60NlYzOyEQvF2= M3PyfHNCVkeHUh?=
EKVX M1zm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT0TWM2OD14LkS2N|IyKM7:TR?= M3\OU3NCVkeHUh?=
NCI-H1648 NH64fHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTZwNke1OVch|ryP NHTLPFVUSU6JRWK=
LB771-HNC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjB[JBKSzVyPU[uPVI{ODFizszN M2LsXnNCVkeHUh?=
SK-MEL-1 NYjuNZp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLkbndIUUN3ME24MlE{OTZ4IN88US=> Mn;RV2FPT0WU
COLO-668 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjKT41RUUN3ME24MlI4Pzh4IN88US=> MoTiV2FPT0WU
EW-12 NFmyToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRThwNEC4NFMh|ryP NEflc4lUSU6JRWK=
A253 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXZdmJZUUN3ME24Mlg1PjZzIN88US=> MUfTRW5ITVJ?
NCI-H2126 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\jRWlEPTB;OD64PVMyQSEQvF2= MVvTRW5ITVJ?
Calu-6 NXWwWm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRThwOUmwOFIh|ryP MoD2V2FPT0WU
NCI-H23 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;jWmIxUUN3ME25MlE4PzR4IN88US=> M1TJfnNCVkeHUh?=
WSU-NHL M374c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTlwN{e0O|gh|ryP M2S3WnNCVkeHUh?=
MMAC-SF NYTYbWYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTlwOUe5NFQh|ryP NUfyRlFTW0GQR1XS
SK-LMS-1 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2juTmlEPTB;MUCuNlg{PCEQvF2= MoLkV2FPT0WU
GCIY M3TqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv5OYhTUUN3ME2xNE42QTJ2IN88US=> M4HBVXNCVkeHUh?=
TE-15 NHPWNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{faNWlEPTB;MUGuOlAxPCEQvF2= MYfTRW5ITVJ?
EoL-1-cell NYLVVWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFzLke2PFIh|ryP M{nKVXNCVkeHUh?=
NCI-H2081 M1HJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpWmlEPTB;MUGuO|c5PiEQvF2= M{LPUXNCVkeHUh?=
EW-3 NF3WVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF{LkK0OlMh|ryP MX7TRW5ITVJ?
CAS-1 NE\EXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLxTWM2OD1zMj6zOlMyKM7:TR?= NUHpW4lkW0GQR1XS
C2BBe1 M{nsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnKzTWM2OD1zMj62NVMyKM7:TR?= M4P6cHNCVkeHUh?=
D-247MG Mo\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K5VWlEPTB;MUKuO|k2OiEQvF2= MX7TRW5ITVJ?
NCI-SNU-5 NFzENXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\KU|Z6UUN3ME2xNk45ODF|IN88US=> NFnkWWVUSU6JRWK=
LS-1034 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF2LkO5O|Uh|ryP NFv6PJJUSU6JRWK=
EW-18 NWnDSoxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF2LkS0PEDPxE1? MXjTRW5ITVJ?
Raji M2\acmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETueWNKSzVyPUG0MlUxPDlizszN M1rrcnNCVkeHUh?=
D-283MED M1na[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrDNYJKSzVyPUG0MlYzPzFizszN M4XWUnNCVkeHUh?=
MZ2-MEL Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:zV2NKSzVyPUG0Mlk3QTZizszN M2HU[3NCVkeHUh?=
NCI-SNU-16 M{H3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nYUGlEPTB;MUWuOFY{OyEQvF2= NIH0OXhUSU6JRWK=
P30-OHK MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF5Lke4N|Eh|ryP MV3TRW5ITVJ?
RXF393 NUPNV2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF7LkCxPFYh|ryP M3;kT3NCVkeHUh?=
NCI-H1395 M{PpdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJyLk[3NFMh|ryP Mmi3V2FPT0WU
U-698-M M1zoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LXbWlEPTB;MkCuO|A4PSEQvF2= M3Xn[nNCVkeHUh?=
NCI-SNU-1 NU\jWG5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJyLkeyNlMh|ryP NXy1VZJbW0GQR1XS
SW684 M1LFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\Hd2lEPTB;MkGuNVcyPiEQvF2= NGnEcYdUSU6JRWK=
NCI-H716 NFvLfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\2NmFVUUN3ME2yNU4{OTV2IN88US=> M1;IZXNCVkeHUh?=
JVM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;adHBKSzVyPUKxMlQyOzNizszN NF7OVXpUSU6JRWK=
NCI-H1581 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\TTWM2OD1{Mj60NVQ5KM7:TR?= MWPTRW5ITVJ?
CA46 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPTTWM2OD1|MT62PVM3KM7:TR?= NHrxXnlUSU6JRWK=
SNB75 NHW5RmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG0OphKSzVyPUOzMlY2ODNizszN MnvkV2FPT0WU
KNS-42 NXvZPVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnaVZdKSzVyPUO1Mlk3OjRizszN NE\JflVUSU6JRWK=
TUR MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;VTWM2OD1|Nj6wOVIyKM7:TR?= NHjRdYlUSU6JRWK=
REH Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHEWXROUUN3ME2zO{45OjFzIN88US=> MXvTRW5ITVJ?
EW-22 M1r4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnJSnBOUUN3ME20Nk4zQDh3IN88US=> MmTjV2FPT0WU
NCI-H446 NXu3e4NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR{Lke4OVMh|ryP MkDiV2FPT0WU
ES3 MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrYTWM2OD12Mz6xN|M6KM7:TR?= M4n1[3NCVkeHUh?=
EW-11 NITZfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTR2LkiyNVgh|ryP M3TD[HNCVkeHUh?=
RH-1 M3uyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;0[21KSzVyPUS3MlU5OTJizszN MoLhV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

- 合併

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

- 合併
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
in solvent
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID